Compositions that enable rapid-acting and highly absorptive intranasal administration

1. A powdery composition for intranasal administration comprising:

i) a non-peptide/non-protein drug, wherein the drug is an opioid receptor agonist, or a 5-hydroxytryptaminel (5-HT 1 ) receptor agonist; and

ii) a carrier consisting essentially of crystalline cellulose aggregate, wherein 85% (w/w) or more of the crystalline cellulose aggregate has a particle size distribution of 20 to 60 μm and wherein when administered to a primate intranasally, the time to maximal blood concentration (Tmax) in said primate is achieved within 20 minutes.

2. The composition of claim 1 , wherein Tmax is achieved within 10 minutes.

3. A powdery composition for intranasal administration comprising:

i) a non-peptide/non-protein drug, wherein the drug is an opioid receptor agonist, or a 5-hydroxytryptaminel (5-HT 1 ) receptor agonist; and

ii) a carrier consisting essentially of crystalline cellulose aggregate, wherein 85% (w/w) or more of the crystalline cellulose aggregate has a particle size distribution of 20 to 60 μm and wherein when administered to a primate intranasally, the absolute bioavailability (BA) of the drug is between 64% to 99%.

4. The powdery composition of claim 1 or 3 , wherein the non-peptide/non-protein drug is sumatriptan, zolmitriptan, morphine or oxycodone.

5. The powdery composition of claim 1 or claim 3 , wherein the non-peptide/non-protein drug is morphine.

6. The powdery composition of claim 1 or claim 3 , wherein the non-peptide/non-protein drug is oxycodone.

7. The powdery composition of claim 1 or claim 3 , wherein the non-peptide/non-protein drug is sumatriptan.

8. The powdery composition of claim 1 or claim 3 , wherein the non-peptide/non-protein drug is zolmitriptan.